CXCR3 and hepatocellular carcinoma: They documented that metformin can inhibit the CXCR3 signaling pathway, which has been linked to sorafenib resistance in HCC cells, promote sorafenib sensitivity in vitro modulating the AMPK signaling pathway and induce metabolic alterations in HCC cells, such as decreasing the glucose uptake and lactate production, which may contribute to its antitumor effects and ability to sensitize HCC cells to sorafenib [104].